RxDoctor Payments Data

Jacquelyn Coster

Acute Care · Houma, LANPI 1396231726

Payments from drug & device makers

What this record shows

This record is dominated by other: $9,083 of the $10,426 with a category attached, or 87.1%. Angiodynamics, Inc. accounts for 87.4% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $6,014, more than ten times the $53 reported in 2021. Among acute care clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,426in general payments, 2019–2025

Across 40 payments — averaging $260.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$9K
  • Kestra Medical Technology Services, Inc.$391
  • Medtronic$162
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$150
  • Abiomed$135
  • AstraZeneca$125
  • plus $356 from 8 others

What the payments were for

  • Food & beverage$1,34313%
  • Other$9,08387%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,426 in reported general payments places this provider in the 95th percentile of 248 acute care providers in Louisiana.

See all acute care providers in Louisiana

Medicare billing

Part B allowed, 2024
$26,040
Medicare patients
201
Services billed
295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$59,878
JardianceEmpagliflozin17$19,949
XareltoRivaroxaban20$16,986
EntrestoSacubitril/Valsartan19$14,321
BrilintaTicagrelor21$9,655
Amiodarone Hcl17$1,150
Nifedipine ErNifedipine14$623
Valsartan14$612
ClopidogrelClopidogrel Bisulfate50$322
Metoprolol Succinate40$278
Isosorbide Mononitrate ErIsosorbide Mononitrate14$158
Atorvastatin Calcium28$152
Nitroglycerin12$106
Furosemide28$61
Gabapentin13$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$59,87888 claims
Johnson & JohnsonXarelto$51$16,98620 claims
AstraZenecaBrilinta$125$9,65521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 acute care providers in Louisiana.

Other acute care in Houma

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →